NCT00553020View on ClinicalTrials.gov

Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

July 31, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin glargine

"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY